A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells


Application of alginate-microencapsulated therapeutic cells is a promising approach for diseases that require a local and constant supply of therapeutic molecules. However most conventional alginate microencapsulation systems are associated with low mechanical stability and protrusion of cells which is associated with higher surface roughness and limits their clinical application. Here we have developed a novel multilayer encapsulation system that prevents cells from protruding from capsules. The system was tested using a therapeutic protein with anti-tumor activity overexpressed in mammalian cells. The cell containing core of the multilayer capsule was formed by flexible alginate, creating a cell sustaining environment. Surrounded by a poly-L-lysine layer the flexible core was enveloped in a high-G alginate matrix that is less flexible and has higher mechanical stability, which does not support cell survival. The cells in the core of the multilayer capsule did not show growth impairment and protein production was normal for periods up to 70 days in vitro. The additional alginate layer also lowered the surface roughness compared to conventional cell containing alginate-PLL capsules. Our system provides a solution for two important, often overlooked phenomena in cell encapsulation: preventing cell protrusion and improving surface roughness.


Immunoisolation of cells for implantation purposes is based on enveloping the cells in a biocompatible and semipermeable membrane that allows diffusion of essential nutrients and therapeutic molecules but prevents deleterious effects of the humoral and cellular part of the host immune system1,2. The technique is proposed for the delivery of cell based therapeutics where local and minute-to-minute release of the active molecule is desired for effective treatment. Encapsulation of living cells for the release of biological therapeutics is under investigation for a variety of diseases such as diabetes3, neurological diseases4,5,6,7 and cancer8,9,10.

A commonly applied technology of immunoisolation is microencapsulation of therapeutic cells in spherical beads made of alginate polymers11 using different encapsulation techniques like electrostatic bead generator, jet cutter, vibrating nozzle and coaxial air driven droplet generator12. Spherical beads are often preferred over discs or tube like structure because of the favorable surface-to-volume ratio which facilitates nutrition of the cells and the release of therapeutic agents11. Another argument to favor microcapsules is the relative small size that allows for transplantation in many sites without interference with the receiving organ11. The latter is an important consideration for example in the treatment of brain tumors, where implantation of microencapsulated cells producing anti-tumor agents has been proposed as an effective approach to delete remnants of malignant cells13,14. Invasive brain tumor cells are impossible to recognize and eliminate during surgery and are a major cause of morbidity.

Microcapsules that are being proposed for diseases such as for the treatment of brain tumors should meet a number of requirements. A key feature in designing immunoisolating microcapsules is avoiding protrusion of cells from capsules. Most conventional alginate encapsulation systems do not meet this prerequisite, as protrusion of cells is more the rule than an exception (figure 1). Protrusion of cells is associated with rejection and fibrotic responses followed by necrosis of the therapeutic cells, which ultimately leads to graft failure15. Another danger is that the therapeutic cells based on cell lines may form tumors themselves when they leak out of the capsules. This is a major safety hurdle preventing the application of cell encapsulation technology in the clinic. Therefore cell based therapy requires a system in which protrusion of cells is prevented.

Figure 1

Cell growth leads to protrusion of cells over time.

Protrusion of cells always occurs in conventional alginate-encapsulation systems.

Alginate is the most commonly applied polymer for cell encapsulation, due to its biocompatibility, ease of processing and heat stable nature16,17. Alginate is a polysaccharide of linear copolymers of (1–4) glycosidically linked α L-guluronic acid (G) and its C-5 epimere, β D-mannuronic acid (M) residues. The relative amount of the two uronic acid monomers as well as their sequential arrangement along the polymer chain differs widely. The uronic acid residues are distributed along the polymer chain in a pattern of binary blocks: G-G blocks, M-M block, or M-G blocks. Based on the composition of G and M residue, alginate is classified as high-G alginate (G content ≥ 60%), intermediate-G alginate (G content in range of 40–60%) and low-G alginate (G content ≤ 40%). The composition as well as the molecular weight of alginate determines the physiochemical properties of the capsules, which also affect cell function18. The aim of the present study was to develop a novel multilayer capsule which overcomes protrusion of cells and high surface roughness while maintaining efficacy of secretion of the therapeutic protein. In the novel system we applied alginate with different mechanical stabilities to facilitate growth of the cells in the core of the capsules but to kill cells that might escape from the capsule and invade the host (figure 2a).

Figure 2

(a) Schematic representation of the novel multilayer capsule concept avoiding protrusion of cells. The core of multilayer capsules facilitates growth of cells while the outer shell of the capsule traps escaping cells and induces cell death. (b) Schematic representation of methodology to generate multilayer capsules. Briefly after coating alginate-PLL capsules, the alginate-PLL capsules are reencapsulated with growth inhibiting 2% high-G alginate matrix. (Details in materials and methods).


To prevent cell protrusion from alginate capsules, we applied different types of alginate to produce gels with different mechanical stability19. The 3.4% intermediate-G alginate beads gelled in 100 mM CaCl2 solution had a rigidity of 9.47 ± 1.61 g and an elasticity of 7.99 ± 0.76 s. The 2% high-G alginate beads were more rigid (11.05 ± 0.77 g) and less elastic (9.12 ± 0.57 s) than 3.4% intermediate-G alginate beads. A too rigid environment will lead to deregulation of cellular metabolism and protein synthesis, eventually leading to cell death. The tests were performed with a mammalian cell lines (BHK cells), as these cells are often applied in preclinical models for the release of therapeutic agents9,20. BHK cells were encapsulated in alginates with two different rigidities and elasticities after which functional survival was studied. The methodology to make multilayer capsules is described in the method section (figure 2b).

Long-term survival and protection of outgrowth of BHK cells in different alginate types

We then investigated the survival of the cells at different periods of time in 3.4% intermediate-G alginate capsules and 2% high-G alginate beads. Cell survival was monitored on a weekly basis and images were acquired on day 1, 7, 14, 21 and day 28 as shown in figure 3. Within 1st week, BHK cells encapsulated in 3.4% intermediate-G alginate started to grow without obstruction and formed cellular clusters. By day 28, these capsules were completely filled with cells. This was very different in the more rigid 2% high-G alginate capsules. Cell growth was impaired when compared to the cells in the 3.4% intermediate-G alginate. On day 28 most of the cells encapsulated in 2% high-G alginate were dark and necrotic indicating that 2% high-G alginate hampers cell survival.

Figure 3

Mechanical stability of alginate influences cell growth.

Phase contrast microscopic images of BHK-cell growth in 3.4% intermediate-G alginate-poly-L-lysine (APA) capsules and 2% high-G alginate beads. APA capsules facilitate cell growth while 2% high-G alginate inhibited cell growth.

Cell behavior in the multilayer system

To determine whether the multilayer system caused an impairment in cell survival, we studied the viability of BHK cells in the multilayer system in comparison to the conventional 3.4% intermediate-G alginate APA capsules. Viability studies were done on at day 1, 7, 14, 21, 28, 35, 49, 56, 63 and day 70. As shown in figure 4a cell survival and growth in both the control 3.4% intermediate-G alginate APA capsules and in the multilayer capsules steadily increased from day 1 to day 70. Cells in the multilayer capsules grew slower. The multilayer capsules were completely filled by day 49, whereas the 3.4% intermediate-G alginate APA capsules were already filled by day 28. Live dead quantification of cells shows approximately 85% of live cells in both conventional and multilayer capsules at any given time point.

Figure 4

Cell growth and survival in intermediate-G alginate APA capsules and in the inner core of multilayer capsules.

(a) Confocal microscope images and quantification (n = 3) of live- dead encapsulated BHK cells in APA capsules and multilayer capsule after live-dead staining at different time points. Live cells emit green fluorescence, dead cells emit red fluorescence. (b) Proof of concept of multilayer capsule: localization of live (green) and dead (red) BHK cells in a multilayer capsule. Protruding cells are effectively killed in multilayer capsules. (c) Western blot (n = 3) analysis of secreted sLrig1 protein (upper band) from BHK-sLrig1 cells encapsulated in multilayer capsules. Multilayer capsules secrete sLrig1 for prolonged periods of time. Bovine serum albumin is visualized by nonspecific binding of secondary antibody (lower band).

Outgrowth of cells in the control capsules was observed by day 14. This was associated with cell growth in the culture flask. In the multilayer capsule cultures we did not observe cells in the flask. Cells in multilayer capsules started to migrate to the outer layer as of day 28, but were trapped effectively and died (figure 4b). To summarize we show that multilayer capsules prevent protrusion of cells in vitro.

Multilayer capsules secrete therapeutic proteins for prolong periods of time

We quantified the secretion of therapeutic sLrig1 from 50 multilayer capsules, cultured in 96 well plates with 100 µl of culture medium. The culture supernatant was collected and replaced with fresh culture medium twice a week from day 14 till day 70. The secretion of sLrig1 was detected by Western blot and quantified as percentage of secretion of sLrig1 with respect to day 14 (figure 4c). The secretion of sLrig1 increased exponentially till day 42, where the highest secretion was observed. After day 42 the secretion was relatively stable with slight fluctuations in secretion of sLrig1 until day 70. As mentioned above traditional 3.4% intermediate-G alginate APA capsules showed protrusion and growth of cells in the culture flask, therefore the secretion of sLrig1 from the APA capsules cannot be reliably quantified. Therefore we restricted quantification of sLrig1 from multilayer capsules.

Cell load and cell growth increases surface roughness of capsules

Surface roughness of the capsules as a consequence of cell growth is correlated with host responses21. We therefore questioned how protrusion of cells influences surface roughness. To this end we studied surface roughness of cell containing APA capsules and multilayer capsules; APA capsules without cells were used as control. Analysis was done on day 30 post encapsulation. As shown in figure 5, APA capsules with cells (Rq = 20.84 ± 15.13) had a significant higher surface roughness compared to empty APA capsules (Rq = 1.65 ± 0.35) (p <0.05). Although there was a tendency that surface roughness of multilayer capsules with cells (Rq = 11.53 ± 2.82) had lower surface roughness compared to APA capsules with cells, the difference was not statistically significant. There was also no significant difference between surface roughness of empty APA capsules and cell containing multilayer capsules. In conclusion we find that cell growth and protrusion increase the surface roughness of capsules and this may be ameliorated in multilayer capsules.

Figure 5

Cell load, cell growth and alginate type affect surface roughness of the capsule.

Surface roughness (Rq) of intermediate-G alginate-PLL-alginate (APA) capsules without cells, with cells and in multilayer capsule with cells on day 30 post encapsulation (n = 4). Cell load increases the surface roughness of capsules. Multilayer capsules with cells show a tendency towards lower surface roughness than APA capsules with cells. Values are expressed as mean ± SD, *p<0.05.


The fact that mechanical strength of alginate influences cell behavior is based on the principle of mechanotransduction. Mechanotransduction is a process by which mechanical forces acting on cells influence biochemical cell behaviour and viability22,23,24. This principle of mechanotransduction was applied to design a multilayer capsule with a minimal risk of protrusion of therapeutic cells. The system does not involve the inclusion of toxic components or any other molecules that might interfere with the survival of the encapsulated cell or with the host tissue. It is simply based on applying a rigidity on the outside of the capsule that is not compatible with cell survival. To our best knowledge we are the first to demonstrate this principle in microencapsulation systems. Different cells require different circumstances for optimal survival18,25. For every cell type it may be necessary to adapt the alginate with cell facilitating and inhibitory properties. Here we used calcium-alginate because the rigidity to kill BHK cells was already reached with this alginate-divalent cation combination. We have also tested the efficacy of multilayer capsules in preventing protrusion of human embryonic kidney cells (supplementary figure 1).The rigidity however can be further enhanced by applying divalent cations with a higher affinity for alginates (Pb>Cu> Cd> Ba> Sr> Ca> Co> Ni> Zn> Mn> Mg)26. Thus by using divalent cations with a higher affinity for alginate such as Pb2+, Cu2+, Cd2+, or Ba2+ the rigidity can be gradually increased27,28. Notably, application of Pb2+, Cu2+ and Cd2+ must be avoided because they are toxic to cells. Another effective method for increasing alginate rigidity is increasing the G-content or increasing the concentration of the alginate to create a mechanotransduction environment not compatible with cell survival. The molecular processes and sensors by which mechanotransduction occurs is still largely unknown23,29. Recent studies have suggested that integrin's play a key role in mechanotransduction30,31. Since alginate lacks integrin binding sites32, non-integrin dependent mechanotransduction may occur which must be responsible for the observed effects on cell behavior33.

Similarly different cells may require different conditions for optimal survival in the capsule core18,25. The advantage of the multilayer system is that the inner capsule is not in direct contact with the microenvironment in the host. This implies that within the multilayer system the balance between optimal biocompatibility in the host and optimal cell-survival environment is less strict34,35,36,37,38. The multilayer system also may improve the surface roughness as shown in figure 5. Another issue that is overcome by the novel system is the reported variations in PLL binding and the associated host responses21,39,40,41. PLL is often applied to the alginate beads in order to reduce the pore size. Immunoprotective systems should protect the encapsulated cells against high molecular weight effector molecules of the adaptive immune system such as immunoglobulins and complement factors2. The PLL capsules usually have a permeability that allows for diffusion of molecules below 160 kDa2,42. However binding of poly-aminoacids to alginate beads is not straightforward. Alginate should form a superhelical core around the PLL and the PLL itself should be forced into β-sheets40. This requires an ion exchange process which if not correctly done leads to host responses against inadequately bound PLL39,41,43,44. This is considered to be one of the factors contributing to the low degree of reproducibility of alginate-polyamino-acid encapsulation38,43,44,45. This binding is less important when the PLL-layer can be covered with an additional layer of alginate with a documented high degree of biocompatibility39,40. Therefore the multilayer capsule procedure may contribute to reproducibility. Moreover the high crosslinking of gelling ions in high-G alginate reduces the pore size of multilayer capsules.

Even though the high crosslinking network obtained with high-G alginate, results in smaller pore sizes and increases rigidity, diffusion of nutrients and secretion of 100 kDa recombinant sLrig1 from encapsulated cells was not obstructed in multilayer capsules. The observed fluctuations in secretion after day 42 can be attributed to cellular contact inhibition or deprivation of nutrients and oxygen in the core of the capsules46. It is difficult to assess the exact concentration of sLrig1 released from the capsules. Based on antibody staining, we can only provide a relative quantification. However the amount of sLrig1 secreted from encapsulated BHK-sLrig1 cells depends on the initial cell concentration and doubling time for cells. With the current settings, we obtained approximately 17 fold increase of sLrig1 secretion per bead on day 42 with respect to day 14. In the past we have shown 40–60% inhibition of glioma growth using 5 alginate beads encapsulated with BHK-sLrig1 cells in mouse models9. It is likely that the initial cell load used for encapsulation and/or number of beads implanted can be increased to achieve higher efficacy.

It might be argued that the rigidity of 11.05 g for the 2% high-G gel is also interfering with host-compatibility or biocompatibility by forming a too stiff layer for host tissues in the vicinity of the capsules. In this study however we applied only alginate-types and concentrations that have already been tested in vivo in different implantation sites including the brain47 and did not show any toxicity or severe response in the host41,47,48. It seems that intracapsular rigidity is a different issue than surface rigidity49,50 which previously has been reported to be a critical issue for biocompatibility51,52.

The surface roughness of microcapsules also plays a crucial role in host responses. A high Rq is associated with enhanced adsorption of proteins and inflammatory cells48,51,52. Although the Rq value of APA capsules with and without cells was not statistically significant from the multilayer capsules with cells, we postulate that providing an additional alginate layer may reduce the variations induced by cell inclusions. In the present study we show that loading the system with cells leads to increased surface roughness as cell free APA capsules had a lower surface roughness than cell containing APA capsules and multilayer capsules. This suggests that inclusion of cells affects the gellification process. Increasing the cell load, hinders the cross linking of gelling ion and as a consequence decreases mechanical stability19. This further increases protrusion and surface roughness. As protrusion is a random phenomenon, protrusion or disruption of the surface structure can occur anywhere on the surface and in different degrees as shown by large standard deviations values in this study. We found that APA-capsules sometimes had Rq values varying in range between 3.34 nm and 40.3 nm. Previous AFM studies have been conducted on cell free capsules which did not report large variations on APA capsules21. We suggest that the variation in surface in cell containing capsules observed in our study may contribute to the reported variations in host responses (biocompatibility) against APA-encapsulated cells. Cell load13,42,53 and surface roughness are interrelated and do matter for in vivo success of implanted capsules51,52. Moreover it has been shown that the Rq of alginate beads increases with increasing affinity of the divalent cations for alginate51,52. By using divalent cations with a higher affinity for alginate the surface roughness of alginate capsules can be gradually increased. Therefore, to keep the surface roughness low on the multilayer system we recommend to use calcium ions as long as high-G alginate is applied.


A system in which protrusion of cells is prevented is mandatory for cell based therapies. In particular with encapsulated therapeutic cell lines, outgrowth of these cells from the capsules may lead to tumor formation. Here we report on a novel microencapsulation system that strongly reduces cell protrusion of cells. Different types of highly biocompatible alginates were applied to facilitate growth and survival of therapeutic cells in the core of the capsules while destroying cells escaping from the core of multilayer capsule. Studies are ongoing to determine the efficacy of this system in pre-clinical models in vivo.


Alginate purification

Alginates of different compositions were obtained from ISP Alginates Ltd UK. Two types of alginates have been purified: 1) intermediate-G alginate (containing 44% G-chain residues, 56% M-chain residues, 23% GG-chain residues, 21% MG-chain residues, 37% MM-chain residues) and 2) high-G alginate (containing 67% G-chain residues, 33% M-chain residues, 54% GG-chain residues, 13% MG-chain residues, 21% MM-chain residues). Alginates were purified in-house as described in detail elsewhere54. Briefly 12–15 gm of crude alginate was dissolved in ice cold 1 mM Na-EGTA (ethylene glycol tetraacetic acid), under constant stirring. The dissolved alginate was filtered through 5 µm, 1.2 µm, 0.8 µm, 0.45 µm filter (Whatman®, Dassel, Germany), to remove visible aggregates. Subsequently the pH of the solution was carefully lowered to 2 with 2 N HCL +20 mM NaCl on ice. Lowering of pH causes alginate to precipitate as alginic acid. Alginic acid precipitate was filtered through a Buchner funnel of pore size 1.5 mm and washed with 1 liter of 0.01N HCL + 20 mM NaCl to remove non precipitated contaminants. Next the proteins from the aggregate alginate acid were removed by chloroform:butanol (4:1 ratio) extraction. The mixture was vigorously shaken for 20 minutes. The suspended mixture was filtered over Buchner funnel. Chloroform:butanol extraction step was repeated twice. Subsequently the alginic acid was then bought into water by slowly and carefully increasing the pH to 7 with 0.5 N NaOH + 20 mM NaCl over a period of at least 1 hr. The alginate solution obtained was further treated with chloroform:butanol (4:1 ratio) to remove proteins which can only be dissolved in at neutral pH. The mixture was centrifuged for 3 minutes at 1800 rpm, which induced the formation of separate chloroform:butanol phase, which was removed by aspiration. This step was repeated one more time. The last step of purification is precipitation of alginate from alginic acid using ethanol. To each 100 ml of alginate solution we added 200 ml absolute ethanol. Constant stirring for 10 minutes in ethanol led to precipitate alginate. The alginate was filtered over the Buchner funnel and washed two times with absolute ethanol. Later, the alginate was washed three times with diethyl ether and was freeze-dried overnight. After purification 3.4% (w/v) intermediate-G alginate and 2% (w/v) high-G alginate were dissolved at 4°C in Krebs–Ringer–Hepes (KRH) with an appropriate osmolarity and further sterilized by 0.2 µm filtration (Corning®, NY, USA).

Mechanical stability of empty beads

Empty beads of 3.4% intermediate-G alginate beads and 2% high-G alginate were made using air driven droplet generator using 23 g needle, gelled in 100 mM CaCl2 for 5 minutes as previously described by us19. Mechanical stability of alginate capsule can be quantified using different methods like burst pressure55, ultrasound56, Young's modulus57, however we prefer to calculate the mechanical stability based on force and time required to resist compression19. The mechanical stability was quantified with a Texture Analyzer XT plus (Stable Micro Systems, Godalming, UK) equipped with a force transducer with a resolution of 1 mN as previously described by us19. Texture Exponent software version 6.0 was used for analyzing the data. Briefly individual beads of size 500 µm micrometer were carefully sorted using a dissection microscope (Leica MZ75 microsystems) equipped with an ocular micrometer with an accuracy of 25 µm. Individual beads were carefully placed on plate, storage solution was carefully removed. The mechanical stability of beads was measured by compressing individual microcapsules to 60% using P/25L mobile probe with a pretest speed of 0.5 mm/sec, a test speed of 0.01 mm/sec and a posttest speed of 2 mm/sec. The trigger force was set to 2 grams. The force exerted by the probe to compress the bead was recorded as function of time.

Cell microencapsulation

Baby hamster kidney (BHK) cells expressing anti-tumor protein sLrig1 (soluble leucine rich repeats and immunoglobulin like domain1) a negative regulator of growth factor signaling9 were grown in DMEM medium supplemented with 4.5 g/L glucose, 10% (v/v) fetal bovine serum (compliment deactivation), 1% (v/v) Antibiotic-Antimycotic (100X) (Sigma-Aldrich,). BHK control and BHK-sLrig1expressing cells at concentrations of 6 × 106 cells per milliliter of sterile 3.4% intermediate-G alginate or 2% high-G alginate were carefully mixed and were transferred into droplets with an electrostatic bead generator, using a 27 g needle. The droplets were collected in 100 mM CaCl2 as gelling solution for 5 minutes. Subsequently, intermediate-G alginate beads were incubated with sterile (0.2 µm filtered) 0.05% poly-L- lysine (PLL) (poly-L-lysine-HCl, Mw 22 kDa, Sigma-Aldrich, The Netherlands) for a period of 3 minutes on ice and 4 minutes at room temperature. PLL coated capsules were subsequently incubated with 0.34% intermediate-G alginate in calcium-free KRH solution with an osmolarity of 310 to form alginate-poly-L-lysine alginate (APA) capsule. Next the cell-containing intermediate-G alginate-PLL membrane was suspended in a 2% high-G alginate solution. After careful mixing the solution was brought in another type of droplet-generator using a 23 g needle and 100 mM CaCl2 as gelling solution58,59. This step is meant to form multilayer capsules. A schematic workflow of making the multilayer capsules is shown in figure 2b. The encapsulated cells were subsequently cultured in 25 cm2 culture flasks containing 5 ml growth medium (Dulbecco's Modified Eagle's culture medium (DMEM) supplemented with 4.5 g/L glucose, 10% (v/v) fetal bovine serum (compliment deactivation), Antibiotic-Antimycotic (100X) 1% (v/v) Sigma-Aldrich,) and kept in a standard tissue culture incubator with 5% CO2, at 37°C. Medium was changed thrice a week. The diameters of the beads and capsules were measured with a dissection microscope (Leica MZ75 microsystems) equipped with an ocular micrometer with an accuracy of 25 µm. The 2% high-G alginate beads and APA capsules had diameter of 250–350 µm while the final multilayer capsules had a diameter of 550–650 µm.

Viability and live-dead quantification of encapsulated cells

Viability of BHK-sLrig1 cells encapsulated in APA capsules and multilayer capsules was studied with a live-dead staining kit of Invitrogen (Calcein AM (4 mM), Ethidium homodimer-1 (2 mM)). Cell containing capsules were washed three times with KRH solution containing 2.5 mM CaCl2. Capsules were incubated in the dark for 30 minutes in 2 ml of serum free medium containing 1 µl of calcein AM and 2 µl of ethidium homodimer-1. Subsequently capsules were washed five times with KRH solution containing 2.5 mM CaCl2. Stained cells in capsules were visualized by a Leica TCS SP2 AOBS confocal microscope and objective HC PL APO CS 10x/0.30 dry, 11 mm. An Argon laser was used for excitation of calcein AM and the emission light over 505 nm and 530 nm was measured for live cells. A Helium Neon 543 nm laser was used for excitation of ethidium homodimer-1 and the emission light over 650 nm detected for dead cells. The pictures of sections were taken through entire Z-axis through the capsules. Imaris (R) x64 version 7.6.4 software was used to process the raw data to construct 3D images and quantify live-dead cells. Viability and live-dead quantification of cells in capsules was determined on day 1, 7, 14, 21, 28, 35, 49, 56, 63 and 70.

Quantification and detection of sLrig1

To quantify the relative secretion of sLrig1 protein from multilayer capsules we carefully sorted 50 multilayer capsules using a dissection microscope (Leica MZ75 microsystems) The 50 individually sorted capsules were placed in 96 well plates and cultured in 100 µl of growth media. Culture supernatants were collected twice a week between day 14 - day 70 by replacing with fresh 100 µl of growth media. Quantification and detection of secreted sLrig1 was done by western blot using goat anti flag monoclonal antibody. Culture supernatant from encapsulated BHK control cells was used as negative control, whereas conditioned media from monolayer BHK-sLrig1 was used as positive control. From day 14 onwards, the volume of the cell culture media was doubled (100 µl to 200 µl) because of increase in cell growth in the capsules. Therefore the volume loaded on the gels was also doubled (to compensate for the 2x dilution). Briefly, 4 µl of culture supernatant of day 14 and 8 µl of culture supernatant from day 21 to day 70 from encapsulated cells were mixed in 1:1 ratio with 1x loading buffer (Invitrogen, Belgium) and resolved on 4–12% NuPAGE® Novex 4–12% Bis-Tris Gel (Invitrogen, Belgium) and transferred to polyvinylidene fluoride (PVDF) membranes (Invitrolon, Invitrogen, Belgium). ECL Advance™ blocking agent 2% (w/v) (GE Healthcare, UK) in Tris-buffered saline containing 0.1% Triton X-100 (TBST) was used for blocking PVDF membrane for at least 2 hours. Goat anti-FLAG mouse monoclonal antibody (1:50000) (Sigma, F1804) was used as primary antibody for the detection of recombinant FLAG-tagged sLrig1. Primary antibody was incubated overnight at 4°C. HRP-conjugated goat anti-mouse antibody (Jackson ImmunoResearch, 115-036-003) was used as secondary antibody (1:150000). The signal was visualized using an ECL™ Advance Western blot detection kit (GE Healthcare, UK). Bovine serum albumin (BSA) was used as housekeeping protein to confirm sample equal loading”. BSA is visualized by nonspecific binding of secondary antibody. ECL image acquisition was performed with an ImageQuant LAS4010 imaging station and signals were quantified with Image Quant TL software (GE Healthcare, Belgium). Data was expressed as a relative percentage of the secretion at day 14.

Surface roughness of capsules

Surface roughness of different area of microcapsules was determined by atomic force microscopy (AFM). APA capsules without cells were used as control. Surface roughness of empty APA capsules (n = 4), APA capsules (n = 4) and multilayer capsules (n = 4) with cells was studied on day 30 post-encapsulation using a Bruker dimensions 3100 atomic force microscopy. Topographic imaging of capsules was performed at room temperature using the tapping mode21,60. Briefly single capsules were carefully sorted using a dissection microscope (Leica MZ75 microsystems), washed with demineralized water and placed on microscopic slides. The excess of water was carefully aspirated. The surface of the microcapsules was scanned by the tip of a silicon nitride cantilever (Nanoprobes GmbH, Darmstadt, Germany), spring constant k was set to 0.05 N/m, which was vertically oscillating (z-oscillating) near its resonant frequency with a tapping frequency (x-y raster scanning) less than 1 Hz. Surface roughness (Rq) was evaluated by using the root mean square average of height deviations taken from the mean image data plane at a 5 µm scan. NanoScope V software was used to analyze the raw data of AFM.

Statistical analysis

Results are expressed as mean ± standard deviation (SD). Anova and Tukey tests were carried out using R software package, version 3.0.0. A p value <0.05 was considered statistically significant.


  1. De Vos, P., Faas, M. M., Strand, B. & Calafiore, R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 27, 5603–5617 (2006).

    CAS  PubMed  Article  Google Scholar 

  2. Kulseng, B., Thu, B., Espevik, T., Skjak-Braek, G. & Skjåk-Braek, G. Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant. 6, 387–394 (1997).

    CAS  PubMed  Article  Google Scholar 

  3. Jacobs-Tulleneers-Thevissen, D. et al. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56, 1605–14 (2013).

    CAS  PubMed  Article  Google Scholar 

  4. Jo, K. Utvik & Simone, P. Niclou. in Bioartifical Pancreas other Biohybrid Ther. (Hallé, J.-P., Vos, P. De & Rosenberg, L.) 607–613 (Transworld Research Network, 2009).

  5. Garcia, P. et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J. Neurosci. 30, 7516–7527 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. Emerich, D. F. & Salzberg, H. C. Update on immunoisolation cell therapy for CNS diseases. Cell Transplant. 10, 3–24 (2001).

    CAS  PubMed  Article  Google Scholar 

  7. Emerich, D. F. et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386, 395–399 (1997).

    CAS  ADS  PubMed  Article  Google Scholar 

  8. Read, T. A. et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. 19, 29–34 (2001).

    CAS  PubMed  Article  Google Scholar 

  9. Johansson, M. et al. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro. Oncol. 15, 1200–11 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Lohr, M. et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591–1592 (2001).

    CAS  PubMed  Article  Google Scholar 

  11. Zimmermann, U. C., Jork, H., Thürmer, A., Zimmermann, F., Fuhr, H., Hasse, G. & Rothmund, C. M. in Biotechnol. Spec. Process. (H.J. Rehm, G. R.) 547–571 (Wiley-VCH Verlag GmbH, 2008).

  12. Prüsse, U. et al. Comparison of different technologies for alginate beads production. Chem. Pap. 62, 364–374 (2008).

    Article  CAS  Google Scholar 

  13. Bhujbal, S. V., de Vos, P. & Niclou, S. P. Drug and Cell Encapsulation: Alternative Delivery Options for the Treatment of Malignant Brain Tumors. Adv. Drug Deliv. Rev. 67–68, 142–53 (2014).

    PubMed  Article  CAS  Google Scholar 

  14. Terzis, A. J. A., Niclou, S. P., Rajcevic, U., Danzeisen, C. & Bjerkvig, R. Cell therapies for glioblastoma. Expert Opin. Biol. Ther. 6, 739–49 (2006).

    CAS  PubMed  Article  Google Scholar 

  15. De Haan, B. J., Faas, M. M. & de Vos, P. Factors influencing insulin secretion from encapsulated islets. Cell Transplant. 12, 617–25 (2003).

    PubMed  Article  Google Scholar 

  16. Uludag, H., De Vos, P. & Tresco, P. A. Technology of mammalian cell encapsulation. Adv. Drug Deliv. Rev. 42, 29–64 (2000).

    CAS  PubMed  Article  Google Scholar 

  17. De Vos, P., Lazarjani, H. A., Poncelet, D. & Faas, M. M. Polymers in cell encapsulation from an enveloped cell perspective. Adv. Drug Deliv. Rev. (2013).

  18. Stabler, C., Wilks, K., Sambanis, A. & Constantinidis, I. The effects of alginate composition on encapsulated betaTC3 cells. Biomaterials 22, 1301–10 (2001).

    CAS  PubMed  Article  Google Scholar 

  19. Bhujbal, S. V., Paredes-Juarez, G. A., Niclou, S. P. & de Vos, P. Factors influencing the mechanical stability of alginate beads applicable for immunoisolation of mammalian cells. J. Mech. Behav. Biomed. Mater. 37C, 196–208 (2014).

    Article  CAS  Google Scholar 

  20. Joki, T. et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol. 19, 35–9 (2001).

    CAS  PubMed  Article  Google Scholar 

  21. Bunger, C. M. et al. Biocompatibility and surface structure of chemically modified immunoisolating alginate-PLL capsules. J. Biomed. Mater. Res. A 67, 1219–1227 (2003).

    CAS  PubMed  Article  Google Scholar 

  22. Orr, A. W., Helmke, B. P., Blackman, B. R. & Schwartz, M. A. Mechanisms of mechanotransduction. Dev. Cell 10, 11–20 (2006).

    CAS  PubMed  Article  Google Scholar 

  23. García, J. R. & García, A. J. Cellular mechanotransduction: Sensing rigidity. Nat. Mater. 13, 539–40 (2014).

    ADS  PubMed  Article  CAS  Google Scholar 

  24. Huselstein, C. et al. Influence of mechanical stress on cell viability. Biorheology 43, 371–5 (2006).

    CAS  PubMed  Google Scholar 

  25. Constantinidis, I., Rask, I., Long, R. C. & Sambanis, A. Effects of alginate composition on the metabolic, secretory and growth characteristics of entrapped beta TC3 mouse insulinoma cells. Biomaterials 20, 2019–27 (1999).

    CAS  PubMed  Article  Google Scholar 

  26. Haug, A. & Smidsrød, O. Selectivity of Some Anionic Polymers for Divalent Metal Ions. Acta Chem. Scand 3, 843–854 (1970).

    Article  Google Scholar 

  27. Mørch, Y. A., Donati, I., Strand, B. L. & Skjak-Braek, G. Effect of Ca2+, Ba2+ and Sr2+ on alginate microbeads. Biomacromolecules 7, 1471–1480 (2006).

    PubMed  Article  CAS  Google Scholar 

  28. Chan, E.-S. et al. Effect of formulation of alginate beads on their mechanical behavior and stiffness. Particuology 9, 228–234 (2011).

    CAS  Article  Google Scholar 

  29. Goldmann, W. H. Mechanotransduction in cells. Cell Biol. Int. 36, 567–70 (2012).

    PubMed  Article  Google Scholar 

  30. Ross, T. D. et al. Integrins in mechanotransduction. Curr. Opin. Cell Biol. 25, 613–8 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. Puklin-Faucher, E. & Sheetz, M. P. The mechanical integrin cycle. J. Cell Sci. 122, 179–86 (2009).

    CAS  PubMed  Article  Google Scholar 

  32. Matthews, B. D., Overby, D. R., Mannix, R. & Ingber, D. E. Cellular adaptation to mechanical stress: role of integrins, Rho, cytoskeletal tension and mechanosensitive ion channels. J. Cell Sci. 119, 508–18 (2006).

    CAS  PubMed  Article  Google Scholar 

  33. Huang, X. et al. Matrix stiffness in three-dimensional systems effects on the behavior of C3A cells. Artif. Organs 37, 166–74 (2013).

    CAS  PubMed  Article  Google Scholar 

  34. Tam, S. K. et al. Biocompatibility and physicochemical characteristics of alginate-polycation microcapsules. Acta Biomater. 7, 1683–92 (2011).

    CAS  PubMed  Article  Google Scholar 

  35. Vos, P. De. et al.Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials 18, 273–278 (1997).

    PubMed  Article  Google Scholar 

  36. Orive, G., Tam, S. K., Pedraz, J. L. J. L., Hallé, J.-P. & Hallé, J.-P. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials 27, 3691–700 (2006).

    CAS  PubMed  Article  Google Scholar 

  37. Tam, S. K. et al. Factors influencing alginate gel biocompatibility. J. Biomed. Mater. Res. A 98, 40–52 (2011).

    PubMed  Article  CAS  Google Scholar 

  38. De Vos, P. et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 30, 2559–70 (2009).

    CAS  PubMed  Article  Google Scholar 

  39. De Vos, P., de Haan, B. J., Kamps, J. A. A. M., Faas, M. M. & Kitano, T. Zeta-potentials of alginate-PLL capsules: a predictive measure for biocompatibility? J. Biomed. Mater. Res. A 80, 813–9 (2007).

    PubMed  Article  CAS  Google Scholar 

  40. De Vos, P., Hoogmoed, C. G. & Busscher, H. J. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J. Biomed. Mater. Res. 60, 252–9 (2002).

    CAS  PubMed  Article  Google Scholar 

  41. De Vos, P., van Hoogmoed, C. G., de Haan, B. J. & Busscher, H. J. Tissue responses against immunoisolating alginate-PLL capsules in the immediate posttransplant period. J. Biomed. Mater. Res. 62, 430–437 (2002).

    CAS  PubMed  Article  Google Scholar 

  42. Strand, B. L. et al. Alginate-polylysine-alginate microcapsules: effect of size reduction on capsule properties. J. Microencapsul. 19, 615–630 (2002).

    CAS  PubMed  Article  Google Scholar 

  43. Strand, B. L. et al. Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant. 10, 263–275 (2001).

    CAS  PubMed  Article  Google Scholar 

  44. Juste, S., Lessard, M., Henley, N., Ménard, M. & Hallé, J.-P. Effect of poly-L-lysine coating on macrophage activation by alginate-based microcapsules: assessment using a new in vitro method. J. Biomed. Mater. Res. A 72, 389–98 (2005).

    PubMed  Article  CAS  Google Scholar 

  45. Vandenbossche, G. M. et al. Host reaction against empty alginate-polylysine microcapsules. Influence of preparation procedure. J. Pharm. Pharmacol. 45, 115–120 (1993).

    CAS  PubMed  Article  Google Scholar 

  46. Zhao, W. et al. Oxygen diffusivity in alginate/chitosan microcapsules. J. Chem. Technol. Biotechnol. 88, 449–455 (2013).

    CAS  Article  Google Scholar 

  47. Kuijlen, J. M. et al. The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors. J. Neurooncol. 78, 31–39 (2006).

    CAS  PubMed  Article  Google Scholar 

  48. De Vos, P., Spasojevic, M., de Haan, B. J. & Faas, M. M. The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules. Biomaterials 33, 5552–9 (2012).

    CAS  PubMed  Article  Google Scholar 

  49. Thu, B. et al. Inhomogeneous alginate gel spheres: an assessment of the polymer gradients by synchrotron radiation-induced X-ray emission, magnetic resonance microimaging and mathematical modeling. Biopolymers 53, 60–71 (2000).

    CAS  PubMed  Article  Google Scholar 

  50. Thu, B., Skjåk-Bræk, G., Micali, F., Vittur, F. & Rizzo, R. The spatial distribution of calcium in alginate gel beads analysed by synchrotron-radiation induced X-ray emission (SRIXE). Carbohydr. Res. 297, 101–105 (1997).

    CAS  Article  Google Scholar 

  51. Machida-Sano, I. et al. Surface characteristics determining the cell compatibility of ionically cross-linked alginate gels. Biomed. Mater. 9, 025007 (2014).

    ADS  PubMed  Article  CAS  Google Scholar 

  52. Lekka, M., Sainz-Serp, D., Kulik, A. J. & Wandrey, C. Hydrogel microspheres: influence of chemical composition on surface morphology, local elastic properties and bulk mechanical characteristics. Langmuir 20, 9968–77 (2004).

    CAS  PubMed  Article  Google Scholar 

  53. De Vos, P., De Haan, B., Pater, J. & Van Schilfgaarde, R. Association between capsule diameter, adequacy of encapsulation and survival of microencapsulated rat islet allografts. Transplantation 62, 893–899 (1996).

    CAS  PubMed  Article  Google Scholar 

  54. De Vos, P., De Haan, B. J., Wolters, G. H., Strubbe, J. H. & Van Schilfgaarde, R. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia 40, 262–270 (1997).

    CAS  PubMed  Article  Google Scholar 

  55. Zimmermann, H. et al. Physical and biological properties of barium cross-linked alginate membranes. Biomaterials 28, 1327–45 (2007).

    CAS  PubMed  Article  Google Scholar 

  56. Albrecht, K., Christian, S., Jörg, B., Birgit, K. & Jörg, K. in Acoust. Imaging (Maev, R. G.) 223–229 (Plenum Publishers, New York, 2002). 10.1007/978-1-4419-8606-1_29.

  57. Wang, C. X., Cowen, C., Zhang, Z. & Thomas, C. R. High-speed compression of single alginate microspheres. Chem. Eng. Sci. 60, 6649–6657 (2005).

    CAS  Article  Google Scholar 

  58. De Vos, P., De Haan, B. J. & Van Schilfgaarde, R. Upscaling the production of microencapsulated pancreatic islets. Biomaterials 18, 1085–90 (1997).

    CAS  PubMed  Article  Google Scholar 

  59. Van Schilfgaarde, R. & de Vos, P. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. J. Mol. Med. (Berl). 77, 199–205 (1999).

    CAS  PubMed  Article  Google Scholar 

  60. Siedlecki, C. A. & Marchant, R. E. Atomic force microscopy for characterization of the biomaterial interface. Biomaterials 19, 441–54 (1998).

    CAS  PubMed  Article  Google Scholar 

Download references

Author information




S.V.B., B.D.H. and P.D.V. designed the experiments. S.V.B. performed and analyzed the experiments with B.D.H. and P.D.V. S.V.B., P.D.V. and S.P.N. wrote the main manuscript. All authors reviewed the manuscript.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Electronic supplementary material

Rights and permissions

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bhujbal, S., de Haan, B., Niclou, S. et al. A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells. Sci Rep 4, 6856 (2014). https://doi.org/10.1038/srep06856

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing